RPS6KA2 and inflammatory bowel disease: Data from the RISK cohort, a treatment-naive pediatric inception cohort, demonstrated a tendency for most methylation signals to revert following treatment,13 notably with the exception of IBD-associated RPS6KA2 hypomethylation, a finding replicated in using this novel cohort (Holm adjusted P = 1.2 × 10-19).